SECOND OPINION: BIG PHARMA’S EGREGIOUS PRICING PRACTICES AND ANTI-COMPETITIVE TACTICS ARE THE ROOT CAUSE OF HIGH DRUG PRICES
Jun 17, 2024
Breaking Down the Facts on Drug Prices, Innovation, Patent Abuse… Read More
© 2025 CSRXP- All Rights Reserved
Updates
DOSE OF REALITY: FORBES: MAKING IT HARDER TO CHALLENGE BIG PHARMA’S PATENT THICKETS WOULD RAISE DRUG PRICES, UNDERMINE TRUE INNOVATION
Jun 5, 2024
Research Article Explores Negative Implications of Proposal to Restrict Key… Read More
DOSE OF REALITY: FORBES: HOW BIG PHARMA STIFLES COMPETITION WITH PRODUCT HOPPING
May 23, 2024
Research Column Explores Case Study in Common Patent Abuse Tactic That… Read More
THEY SAID IT!: LAWMAKERS ROAST BIG PHARMA’S PATENT ABUSE, CALL FOR ACTION ON BIPARTISAN SOLUTIONS TO HOLD THE PHARMACEUTICAL INDUSTRY ACCOUNTABLE
May 22, 2024
Senate Judiciary Committee Puts Spotlight on Big Pharma’s Anti-Competitive… Read More
DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH
May 21, 2024
Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold… Read More
DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL
May 16, 2024
Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on… Read More
DOSE OF REALITY: IQVIA REPORT SHOWS HOW BIG PHARMA’S EGREGIOUS PRICING PRACTICES DRIVE INCREASED PRESCRIPTION DRUG SPENDING
May 10, 2024
Analysis Shows Price Hikes Outpacing Inflation, Rising Launch Prices and… Read More
BIG PHARMA EARNINGS WATCH: ELI LILLY, NOVO NORDISK, ABBVIE, AMGEN, GLAXOSMITHKLINE AND PFIZER
May 6, 2024
Repeated Price Hikes and Egregious Prices on GLP-1 Weight Loss Drugs Boost… Read More
DOSE OF REALITY: BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM
May 2, 2024
Reports Find Biosimilars Have Lower Prices Than Brand Name Biologics… Read More
CSRXP APPLAUDS EXPANDED FTC CRACK DOWN ON BIG PHARMA’S SHAM PATENTS IN THE ORANGE BOOK
Apr 30, 2024
Commission Builds on Previous Action by Targeting More Than 300 Patents,… Read More
BIG PHARMA EARNINGS WATCH: NOVARTIS, MERCK, ASTRAZENECA, BRISTOL MYERS SQUIBB AND SANOFI
Apr 26, 2024
Big Pharma Continues Raking in Big Profits and Expectation-Beating Revenue… Read More
DOSE OF REALITY: NEW ANALYSES UNDERSCORE HOW BIG PHARMA’S EGREGIOUS PRICING OF WEIGHT LOSS DRUGS IS UNSUSTAINABLE
Apr 25, 2024
Two Reports Explore Cost for U.S. Patients and the U.S. Health Care System of… Read More